The metabolism of ondansetron
- PMID: 2533904
The metabolism of ondansetron
Abstract
The metabolism of ondansetron has been studied in rat, dog and man. In laboratory animals absorption of the compound across the gastrointestinal tract is rapid and extensive, but due to high first-pass metabolism, the oral systemic bioavailability is low (less than 10%). The high systemic clearance of ondansetron results in a very short half-life in rat and dog. The renal clearance of ondansetron is low, indicating that the major route of systemic clearance is by metabolism. Routes of excretion of drug-related material differ between laboratory animals and man - the major route in the rat and dog is via the bile, while in man the predominant route is via the urine. However, the routes of metabolism are qualitatively similar in all species, indicating that the species used in toxicological testing of ondansetron were appropriate.
Similar articles
-
The clinical pharmacology of ondansetron.Eur J Cancer Clin Oncol. 1989;25 Suppl 1:S21-4; discussion S25-7. Eur J Cancer Clin Oncol. 1989. PMID: 2533895 Review.
-
Dose-independent pharmacokinetics of ondansetron in rats: contribution of hepatic and intestinal first-pass effects to low bioavailability.Biopharm Drug Dispos. 2008 Oct;29(7):414-26. doi: 10.1002/bdd.628. Biopharm Drug Dispos. 2008. PMID: 18697186
-
Pharmacokinetics and metabolism of the new thromboxane A2 receptor antagonist ramatroban in animals. 1st communication: absorption, concentrations in plasma, metabolism, and excretion after single administration to rats and dogs.Arzneimittelforschung. 1997 Aug;47(8):928-38. Arzneimittelforschung. 1997. PMID: 9296279
-
The determination in plasma and pharmacokinetics of ondansetron.Eur J Cancer Clin Oncol. 1989;25 Suppl 1:S71-4. Eur J Cancer Clin Oncol. 1989. PMID: 2533903
-
Ondansetron metabolism and pharmacokinetics.Semin Oncol. 1992 Aug;19(4 Suppl 10):9-15. Semin Oncol. 1992. PMID: 1387254 Review.
Cited by
-
Pharmacokinetic optimisation of antiemetic therapy.Clin Pharmacokinet. 1992 Aug;23(2):147-60. doi: 10.2165/00003088-199223020-00006. Clin Pharmacokinet. 1992. PMID: 1355018 Review.
-
Ondansetron clinical pharmacokinetics.Clin Pharmacokinet. 1995 Aug;29(2):95-109. doi: 10.2165/00003088-199529020-00004. Clin Pharmacokinet. 1995. PMID: 7586904 Review.
-
The pharmacokinetics of intravenous ondansetron in patients with hepatic impairment.Br J Clin Pharmacol. 1993 Apr;35(4):441-3. doi: 10.1111/j.1365-2125.1993.tb04164.x. Br J Clin Pharmacol. 1993. PMID: 8485026 Free PMC article.
-
PharmGKB summary: Ondansetron and tropisetron pathways, pharmacokinetics and pharmacodynamics.Pharmacogenet Genomics. 2019 Jun;29(4):91-97. doi: 10.1097/FPC.0000000000000369. Pharmacogenet Genomics. 2019. PMID: 30672837 Free PMC article. No abstract available.
-
Comparative Pharmacology and Guide to the Use of the Serotonin 5-HT3 Receptor Antagonists for Postoperative Nausea and Vomiting.Drugs. 2016 Dec;76(18):1719-1735. doi: 10.1007/s40265-016-0663-3. Drugs. 2016. PMID: 27988869 Review.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Molecular Biology Databases